Top Premarket Decliners
8:08AM ET 6/03/2022 MT NewswiresBit Origin (BTOG) shares slumped 40% after the company initiated a public offering of common stock. TC Biopharm (TCBP) shares tumbled 35% after the company...
Quotes Snapshot > IDRA
Idera Pharmaceuticals Inc IDRA:NASDAQ
Last Price$0.44NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22
Today's Change0(0.00%)
Bid (Size)$0.44 (4)
Ask (Size)$0.49 (127)
Day Low / HighN/A - N/A
Volume83.5 K
Read more news Recent News
Idera Halts Enrollment in Mid-Stage Trial for Tilsotolimod in Melanoma Patients After Meeting Primary Endpoint
9:34AM ET 5/17/2022 MT NewswiresIdera Pharmaceuticals (IDRA) said Tuesday that it has halted enrollment in a mid-stage clinical trial for its toll-like receptor 9 agonist tilsotolimod in...
View all Commentary and Analysis
No news stories available at this time.
Company Profile
Business DescriptionIdera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. View company web site for more details
| Address | 505 Eagleview Boulevard Exton, Pennsylvania 19341 |
| Phone | +1.484.348.1600 |
| Number of Employees | 36 |
| Recent SEC Filing | 07/01/2022 SC 13D/A |
| President, Chief Executive Officer & Director | Vin Milano |
| Chief Operating Officer & Senior Vice President | Don Soland |
| Chief Financial Officer & Senior Vice President | John J. Kirby |
| Secretary, Senior VP & General Counsel | Bryant Lim |
Company Highlights
| Price Open | $0.43 |
| Previous Close | $0.46 |
| 52 Week Range | $0.30 - 1.22 |
| Market Capitalization | $23.2 M |
| Shares Outstanding | 53.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.42 |
| Beta vs. S&P 500 | N/A |
| Revenue | $662.0 K |
| Net Profit Margin | N/A |
| Return on Equity | -69.27% |
Analyst Ratings as of 06/26/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |